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Sommario 
La proteina Sinaptosomiale di 25 KDa (SNAP-25) è una proteina SNARE coinvolta 
nel processo di esocitosi dei neurotrasmettitori dalle vescicole sinaptiche, processo 
che risulta alterato nella malattia di Alzheimer (AD). E' stato evidenziato che, 
variazioni dei livelli di SNAP-25, contribuiscono al declino di funzioni cognitive 
legate all'invecchiamento e che polimorfismi a singolo nucleotide (SNPs) del gene 
SNAP-25 correlano con patologie neuropsichiatriche, giocando un ruolo importante 
nella determinazione del fenotipo del QI. Per verificare il possibile coinvolgimento 
di SNAP-25 nell'AD sono stati analizzati cinque polimorfismi genici in pazienti 
affetti da AD (N=607), replicando lo studio in soggetti con decadimento cognitivo 
lieve di tipo amnesico (aMCI)(N=154) e in due gruppi di controlli sani, comparati 
per età e sesso (HC1: N=615 e HC2: N=310). I risultati hanno mostrato che gli 
alleli intronici rs363050(A) e rs363043(T), così come l'aplotipo rs363050/rs363043 
A-T sono statisticamente più frequenti sia in AD che in aMCI. Ulteriori analisi hanno 
indicato che questi alleli ed aplotipo sono associati con punteggi patologici di 
fluenza categorica in pazienti AD. Infine, i genotipi di SNAP-25 correlano con una 
significativa ridotta attività cerebrale nella corteccia cingolata e nelle aree frontale 
(circonvoluzione media e superiore) e temporo- parietale (circonvoluzione 
angolare), come misurato dalle analisi di fMRI. In conclusione, dato che i 
polimorfismi di SNAP-25 sono associati con AD e correlano con alterazioni di 
fluenza categorica e con una ridotta e localizzata attività cerebrale, potrebbero 
essere utilizzati come markers per la diagnosi di AD e di deficit cognitivi. E' stata 
studiata, in seconda battuta, la possibile correlazione tra APOE4, gli SNPs di 
SNAP-25 e l'outcome della terapia a stimolazione multidimensionale (MST). 
Cinquantotto individui con diagnosi clinica di probabile o possibile AD, e fase di 
progressione da media a moderata, sono stati sottoposti a trattamento MST per 10 
settimane. I soggetti sono stati sottoposti a test cognitivi, comportamentali e 
funzionali tramite le scale; Mini Mental Scale Evaluation (MMSE), Functional Living 
Skill Assessment (FLSA) e Neuropsychiatric Inventory Scale (NPI), sia prima del 
trattamento che alla fine della terapia. I genotipi analizzati per APOE e gli SNPs di 
SNAP-25 sono stati correlati con i punteggi ΔMMSE, ΔNPI and ΔFLSA tramite 
analisi di regressione logistica multinomiale. I risultati mostrano punteggi di MMSE 
più alti dopo la riabilitazione in soggetti APOE4 negativi comparati con i pazienti 
APOE4 positivi; mentre gli alleli di SNAP-25 rs363050(G) e rs363039(A) correlano 
con un significativo miglioramento comportamentale dopo trattamento MST. Le 
analisi aplotipiche degli SNPs di SNAP-25 hanno evidenziano la presenza di un 
associazione significativa tra l'aplotipo di SNAP-25 e bassi punteggi di ΔNPI. In 
particolare l'aplotipo rs363050(G)-rs363039(A)-rs363043(C): (GAC) è stato 
associato a miglioramento comportamentale secondo la scala NPI. In conclusione i 
polimorfismi in geni con attività di modulazione della plasticità neuronale 
potrebbero predire l'outcome di una riabilitazione multistrutturata per l'AD. 
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Abstract 
Synaptosomal-associated protein of 25kDa (SNAP-25) is an age-regulated 
vesicular SNARE protein involved in the exocytosis of neurotransmitters from 
synapses, a process that is altered in Alzheimer’s disease (AD). Changes in 
SNAP-25 levels are suggested to contribute to age-related decline of cognitive 
function, and single nucleotide polymorphisms (SNPs) in the SNAP-25 gene are 
present in neuropsychiatric conditions and play a role in determining IQ 
phenotypes. To verify a possible role of SNAP-25 in AD we analyzed five gene 
polymorphisms in patients with AD (N=607), replicating the study in subjects with 
amnestic mild cognitive impairment (aMCI)(N=154) and in two groups of age-
matched healthy controls (HC1: N=615 and HC2: N=310). Results showed that the 
intronic rs363050(A) and rs363043(T) alleles, as well as the rs363050/rs363043 A-
T haplotype are significantly more frequent in both AD and aMCI. Further analyses 
indicated that these alleles and haplotype are associated with pathological scores 
of categorical fluency in AD alone. Finally, SNAP-25 genotypes correlated with a 
significantly decreased brain activity in the cingulate cortex and in the frontal 
(middle and superior gyri) and the temporo- parietal (angular gyrus) area, as 
measured by fMRI. SNAP-25 polymorphisms are associated with AD and correlate 
with alterations in categorical fluency and a reduced localized brain activity. In 
conclusion SNAP-25 polymorphisms could be suggested as surrogate markers for 
the diagnosis of AD and of cognitive deficit; these SNPs might also have a possible 
predictive role in the natural history of AD. Moreover we investigated a possible 
correlations between APOE4 and SNAP-25 polymorphisms and the outcome of a 
multidimensional cognitive, behavioral and functional stimulation (MST). Fifty-eight 
individuals with mild-to-moderate AD underwent MST for 10 weeks. Mini Mental 
Scale Evaluation (MMSE), Functional Living Skills Assessment (FLSA) and 
Neuropsychiatric Inventory scale (NPI) were performed at baseline and after 
therapy. Molecular genotyping of ApoE4 and SNAP-25 SNPs were correlated with 
ΔMMSE, ΔNPI and ΔFLSA scores by multinomial logistic regression analysis. 
Results shown higher overall MMSE scores after rehabilitation in ApoE4 negative 
compared to ApoE4 positive patients, whereas the SNAP-25 rs363050(G) and 
rs363039(A) alleles correlated specifically with significant improvements in 
behavioural parameters after MST. Haplotype analysis of  rs363050, rs363039 and 
rs363043 SNAP-25 SNPs showed the presence of a significant association 
between SNAP-25 haplotypes and lower ΔNPI. In particular the rs363050(G)-
rs363039(A)-rs363043(C): (GAC) haplotype was statistically associated with a 
better outcome of treatment as measured by the NPI scale. In conclusion 
polymorphisms in genes known to modulate neural plasticity may predict the 
outcome of a multistructured rehabilitation protocol in AD. 
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Chapter I 
1. INTRODUCTION 
 
1.1 Alzheimer's Disease  
 
1.1.1 History 
Alzheimer's Disease (AD) was described for the first time in 1907 by 
Aloysius Alzheimer a German neurologist and psychiatrist. He described 
the behavioral manifestations of “senile dementia” in a 51-year-old female 
named Auguste D. Moreover he was the first to recognize the significance 
of the senile plaques and neurofibrillary tangles found in her brain after her 
death at age 55 years [1,2]. Dr. Alzheimer’s lecture about the first case of 
the fatal progressive dementia did not receive special attention, although as 
a psychiatrist he was a pioneer at this time by associating pathological 
changes with dementia symptoms. Alzheimer’s colleague, Kraepelin, finally 
gave the disease its official name in 1910. Since then accumulating 
evidence and knowledge have been accumulated in this research  field. 
Amyloid fibrils from tissue were visualized for the first time in 1959 by 
electron microscopy. X-Ray diffraction studies of isolated fibrils revealed 
the cross β structure as a common motif in 1968 [3]. In 1970, thanks to the 
amino acid analysis and protein sequencing tools was revealed that each 
amyloidosis is linked to specific protein [4]. In 1984, Aβ was identified as 
the major component of plaques from AD patients [5]. The Tau protein, 
already know as essential protein for microtubule assembly [6], was 
identified as the neurofibrillary tangle forming protein in 1985. The 
corresponding MAPT gene was cloned in 1988 [7], one year after the 
amyloid- β protein precursor (βAPP) gene containing the Aβ sequence was 
cloned from chromosome 21 [8]. Few years later, based on the strong 
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association between APOE and Aβ in the brain [9], APOE was suggested 
as Aβ-binding protein that induces a pathological β sheet conformational 
change in Aβ [10]. 
 
1.1.2 Introduction to the pathology 
Alzheimer’s disease is a chronic and progressive neurodegenerative 
disorder, and it is the most common age-related dementing illness. Actually 
is estimated that AD affect 35.6 million individuals worldwide and the 
number of patients increases every year and recent projections predict 65 
millions of AD worldwide by 2030 [11]. AD is the most common type of 
dementia, accounting for 60-80% of all the cases [12] and affecting people 
aged 65 with an incidence of 25-50% [13].  
Dementia is characterized by the loss of or decline in memory and other 
cognitive abilities. It is caused by various diseases and conditions that 
result in damaged brain cells. To make a diagnosis of dementia, physicians 
commonly refer to the criteria reported in the Diagnostic and Statistical 
Manual of Mental Disorder, Fourth Edition (DSM-IV) [14]. 
To be classified as dementia, the following DSM-IV criteria are required: 
symptoms must include decline in memory and decline in at least one of 
the following cognitive abilities: 
 Ability to generate coherent speech; 
 Ability to understand spoken or written language; 
 Ability to identify or recognize objects, assuming intact sensory 
function; 
 Ability to execute motor activities, that include motor and sensory 
abilities and comprehension of the required task; 
 Ability to think abstractly, make sound judgments and plan and carry 
out complex tasks. 
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The impairment in cognitive abilities must be severe enough to interfere 
with daily life. 
Moreover it is important for a physician to evaluate and determine the right 
cause of memory loss or other dementia-like symptoms. In fact some 
symptoms can be reversed if are caused by depression, delirium, drugs 
interaction, thyroid problems, alcohol abuse or vitamin deficiencies that are 
treatable condition. Otherwise, if symptoms of dementia are not caused by 
treatable condition, further assessments must be conducted by a physician 
to identify the form of dementia that is causing the symptoms. Different type 
of dementia are associated with distinct symptom patterns and 
characteristic microscopic brain abnormalities. Evidence from long-term 
observational and autopsy studies indicates that many people with 
dementia have brain abnormalities associated with more than one type of 
dementia. Despite the great scientific progress and the important discovery 
made in the last 100 years, the cause or causes of AD remain unknown. As 
yet, neither a satisfying therapy nor a preventative cure is available. 
Moreover AD can be precisely diagnosed post-mortem with analysis of 
neurological condition through the Braak staging, that could precisely 
classify the progress of the disease [15]. 
 
1.1.3 Symptoms of Alzheimer's disease 
AD can affect people in different ways, but one of the most common signs 
of Alzheimer's is memory loss, especially forgetting recently learned 
information. This may be due to the disruption of brain cell function that 
usually begins in regions involved in the formation of new memories. As 
suggested by the Alzheimer's Association (www.Alz.org) there are 10 
warning signs and symptoms. Every individual may experience one or more 
of these signs in different degrees: memory loss that disrupts daily life; 
challenges in planning or solving problems; difficulty completing familiar 
tasks at home, at work, or at leisure; confusion with time or place; trouble 
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understanding visual images and spatial relationships; new problems with 
words in speaking or writing; misplacing things and losing the ability to 
retrace steps; decreased or poor judgment; withdrawal from work or social 
activities; changes in mood and personality. 
The pathological progression from mild to moderate and severe AD can 
take place at different rates. As the disease progresses the individual's 
cognitive and functional abilities decline. In advanced stage of AD, patients 
need help with the basic activities of the daily living (ADLs) as bathing, 
dressing and eating. In the final stage of the disease, people with AD lose 
their ability to communicate, to recognize loved ones and become bed-
bound and reliant on a full-time caregiver. In the final stage of AD the 
inability to move becomes so dangerous that could expose the patient to 
infections including pneumonia. The AD-related pneumonia result fatal for 
the patients. While families generally prefer to keep the person with AD at 
home as long as possible, most of them eventually move into a nursing 
home where professional caregiver are available for better care [16]. 
 
1.1.4 Diagnosis of Alzheimer's disease 
The National Institute on Aging (NIA) and the Alzheimer's Association 
recommended new diagnostic criteria and guidelines for AD in 2011. The 
new criteria and guidelines update, refine and broaden the guidelines 
published in 1984 by the Alzheimer's Association and the National Institute 
of Neurological Disorders and Stroke (NINDS). The work for the new 
criteria and guidelines began in 2009 when more than 40 researchers and 
clinicians in the AD field began an in-depth review of the 1984's criteria to 
decide how they might be improved by incorporating scientific advances. 
The new criteria and guidelines  differ from the original one, based chiefly 
on a doctor's clinical judgment about the cause of a patient's symptoms, 
taking into account reports from the patient, family members and friend, 
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results of cognitive testing and general neurological assessment, in two 
main aspects: 
 Identification of three stages of AD;  
 Inclusion of biomarker tests such as levels of certain proteins in 
fluids (e.g. levels of tau and amyloid-β in the cerebrospinal fluid and 
blood). 
The three stages of AD identified are: preclinical AD; mild cognitive 
impairment (MCI) due to AD; dementia due to AD.  
The first stage, preclinical AD, occurring before symptoms such as memory 
loss develop and before the affection of one’s abilities to carry out everyday 
activities. Individuals in this stage have measurable change in the brain, 
cerebrospinal fluid and/or blood biomarkers that indicate the earliest signs 
of disease. When these very early changes in the brain are identified, an 
individual diagnosed using the new criteria would be said to have preclinical 
AD or MCI due to AD. The second stage, MCI due to AD, indicate 
individuals having mild, but measurable, changes in thinking abilities that 
are noticeable to the person affected, to the family members and friends, 
but that don't affect the individual's ability to perform the daily activities. 
The third stage, dementia due to AD, is characterized by memory, thinking 
and behavioural symptoms that impair ability and function in daily life, 
caused by AD related processes. 
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1.1.5 Etiology of Alzheimer's disease 
The causes of AD, a condition characterized by progressive 
neurodegeneration and gradual cognitive impairment, are still unclear. 
Experts believe that Alzheimer's develops as a complex result of multiple 
factors rather than any one overriding cause. Both age and genetics have 
been identified as risk factors. An estimated 1% of AD cases develop the 
disease as result of a genetic mutation [17], involving the gene for the 
amyloid precursor protein (APP) and the genes for the Presenilin 1 and 2 
(PSEN1 and PSEN2). Inheriting any of these genetic mutations guarantees 
that an individual will develop AD, in fact disease symptoms tend to 
develop before the age of 65 years. In this scenario the disease is 
considered early-onset familial AD (EOFAD) [18]. The other AD cases, like 
common chronic disease, appear to be sporadic and to have a later age at 
onset of more than 65 years (LOAD) [19]. 
Experts believe that AD, except for the sporadic cases, develops as a result 
of multiple factor rather than a single cause including: aging, injury, low 
educational levels, hyperlipidemia, homocysteinemia, diabetes mellitus and 
obesity [20-23]. 
 
1.1.5.1 Age 
Aging is the most important known non-genetic risk factor for AD. Most 
people with AD are diagnosed at 65 years or older [24]. 
People younger than 65 years can also develop the disease, although this 
is much rarer. While age is the greatest risk factor, AD is not a normal part 
of aging and advanced age alone is not sufficient to cause the disease. 
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1.1.5.2 Genetics 
Combination of environmental risk factors with genetic background, as 
APOE4, may further increase the risk for the LOAD and age-related decline 
[25]. As described before AD cases can be divided into LOAD and EOFAD 
subtypes. The EOFAD have an autosomal dominant inheritance linked to 3 
genes: APP, PSEN1 and PSEN2, whereas the LOAD form has been 
consistently associated with only one gene, APOE.  
In EOFAD subjects, mutation affect APP processing, leading to an altered 
production of different Aβ peptides and, thus, their relative ratios. In Down's 
syndrome, patients carry an extra copy of chromosome 21, on which APP 
gene resides, it was noticed a develop of early-onset dementia with 
pathological hallmarks of AD in subject's brain [26], consistent with the idea 
that over-expression of APP could cause early-onset AD. In strong support 
of this idea, APP locus duplication leads to early-onset AD [27]. Moreover 
genetic variation in the promoter sequence, which might cause an 
increased APP gene expression, may be a risk factor for late-onset, with 
the levels of APP expression correlating inversely with age of disease onset 
[28].  
While EOFAD is caused by rare and high penetrant mutation in three 
genes, the genetics of LOAD is more complex. Aging is the major non-
genetic risk factor for LOAD. Instead, APOE gene, on chromosome 19, in 
particular the allele -ε4, has been identified as the major genetic risk factor. 
APOE4, genetically linked to sporadic AD, has a gene-dose effect on 
increasing the risk and lowering the age of onset of the disease [29]. 
Indeed, subject that inherit one copy of APOE4 have an increased risk to 
develop AD, and subject that inherit two copy show an higher risk. 
Genome-wide association studies, performed on late-onset AD subjects 
from different population around the world, identified APOE4 as the top 
gene with extremely high confidence in LOAD [30]. The estimated risk of 
developing AD in individuals with two copies of APOE4 allele (~2% of the 
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population) is the ~60% at 85 years, and for those with one copy of the 
APOE4 allele (~25% of the population) is the ~30% by the same age. 
Compared to APOE4 carriers, the risk for AD in subjects with two copies of 
APOE3 allele is ~10% by the age of 85 years. Therefore, APOE gene 
should be considered as major gene, with semi dominant inheritance, for 
LOAD [31]. Unlike inheriting a known genetic mutation that causes AD, 
inheriting the ɛ4 form of the APOE gene does not guarantee that an 
individual will develop AD. Moreover, genome-wide association studies also 
identified other genes that modulate the risk of late-onset of AD, including 
CLU, CR1, PICALM, BIN1, SORL1, GAB2, ABCA7, MS4A4/MS4A6E, 
CD2AP, CD33, EPHA1 and HLA-DRB1/5 [30]. However, the relative 
contribution of these genes to AD is modest as compared to APOE4. 
 
1.1.5.3 Epigenetic 
Epigenetic is a "stably heritable phenotype resulting from changes in a 
chromosome without alterations in the DNA sequence" [32], these changes 
refers to modification in gene expression influenced by DNA methylation 
and/or chromatin structure, RNA editing and RNA interference [33]. 
Dysregulation in epigenetic mechanisms could lead to cognitive disorders 
that affect learning and memory as seen in AD [34]. Studies on post-
mortem brain samples, as well as transgenic animal models, have shown 
that AD and aging are associated with epigenetic dysregulation, including 
abnormal DNA methylation and histone modifications. Despite this, it is not 
clear whether the epigenetic changes observed in AD represent a cause or 
a consequence of the disease, twin study support the hypothesis that 
epigenetic mechanism modulate AD risk [35]. 
 
1.1.5.4 Education 
Researchers found that education plays a crucial role in the prevalence of 
AD or other dementia [36]. 
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People with fewer years of education are at a higher risk than those with 
more years of education [37]. The exact cause for this relationship is 
unknown, but it is theorized that a higher education level leads to the 
formation of more synaptic connections in the brain. This creates a 
“cognitive reserve” in the brain [38], enabling subjects to better compensate 
for changes in the brain that could result in symptoms of AD by using 
alternate routes of neuron-to-neuron communication to complete a 
cognitive task [39]. 
 
1.1.6 Treatment of AD 
 
1.1.6.1 Pharmacologic treatment 
The aim of drugs administration is to slow or stop an illness or treat its 
symptoms. Unfortunately none of the treatments available today for AD 
slows or stops neurons malfunction and death in the brain. Until now, few 
drugs have been approved by the US Food and Drug Administration that 
temporarily improve symptoms of AD by increasing the amount 
neurotransmitters in the brain. The effectiveness of these drugs varies from 
person to person. Three of this drugs are acetylcholine esterase inhibitors 
(Donepezil, Rivastigmine, Galantamine), which are licensed for the 
treatment of people with mild-to-moderate AD, and Memantine, an NMDA 
receptor antagonist, which is licensed for the treatment of people with 
moderate-to-severe AD. The existing drugs do not specifically target the 
underlying pathology of AD. Instead, current treatments target cholinergic 
or glutamatergic function. Cholinergic function is compromised in AD [40] 
following early loss of basal forebrain cholinergic neurons. Treatments 
mainly focus on inhibition of acetylcholine esterase or modulation of 
muscarinic and nicotinic acetylcholine receptors.  
Treatment with acetylcholinesterase inhibitors results in a moderate 
improvement in cognition (1.5-2 points on the MMSE over 6-12 months), 
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short-term (3-6 months) improvement in global outcome and some 
additional short-term stabilization of overall cognitive function [41, 42]. 
There is also more limited evidence of modest improvements in mood 
(particularly apathy) and social interaction [43]. 
 
1.1.6.2 Non-pharmacologic treatment 
The non-pharmacological treatment are approaches that use physical 
therapy and reminiscence therapy. Even if, as pharmacologic treatment, 
non-pharmacologic therapies have not been shown to alter the course of 
AD, these therapies are often used with the goal of maintaining cognitive 
function, helping brain to compensate for impairment, improving quality of 
life or reducing behavioral symptoms such depression, apathy, wandering, 
sleep disturbances, agitation, and aggression. A wide range of non-
pharmacologic therapies have been proposed and studied, but of all that's 
categories, reviewed in the Cochrane Database only cognitive stimulation 
suggested a beneficial effect. Moreover, of the high-quality studies 
reviewed, cognitive training, cognitive stimulation and ADLs training 
appeared most successful in reaching the aims of the intervention [44]. 
The most successful non-pharmacologic interventions, founded by a meta-
analysis which combines results from many studies, seems to be a 
multicomponent intervention, which have the potential to reduce the 
frequency and severity of behavioral and psychological symptoms of 
dementia. This treatment is also tailored to the needs of the patient and the 
caregiver and delivered at home with periodic follow-up [45]. Based on this 
findings, a multidimensional stimulation approach [46] was developed using 
Cognitive Stimulation (CS), recreational/occupational and 
psychomotor/physical therapy to set up a Multidimensional Stimulation 
Therapy (MST) [47-49]. This MST was demonstrated to improve cognitive 
and behavioral disturbances. Moreover the MST treatment increase the 
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activation of temporal areas in the right insular cortex and in the thalamus, 
as determined by fMRI [50]. 
 
1.2 Genes and Biomarker research 
 
1.2.1 Apolipoprotein E 
The APOE gene is located on chromosome 19q13.2 and encodes a 299 
amino acids long glycoprotein of 34.1 kDa [51]. It is synthesized in various 
tissues including liver, brain, skin and macrophages [52]. APOE plays 
multiple roles in the regulation of lipid and lipoprotein levels in the blood. 
APOE serves as ligand for members of very-low-density lipoprotein (VLDL), 
low-density lipoprotein (LDL) receptor family, high-density lipoproteins 
(HDL) and is involved in the removal of lipoproteins from the circulation for 
the excretion in the liver. APOE and APOE isoforms functions may extend 
beyond lipid metabolism to include maintenance of normal brain function 
[53]. The protein contains two major structural domains, including a 
compact stable globular amino-terminal domain (amino acid residues 20-
166) and a less-stable carboxy-terminal domain (amino acid residues 225-
299). These domains are connected by a hinge region (amino acid residues 
166-224) [54]. The LDL receptor-binding region is between residues 136-
150 of the protein, where multiple basic amino acids are present [55]. The 
major lipid-binding region is contained in the carboxy-terminal domain [56]. 
The amino acid residues 245-266 are critical for binding to VLDL particles, 
whereas binding to HDL occurs even without the carboxyl-terminal domain 
[57]. 
Several individual Single Nucleotide Polymorphisms (SNPs) have been 
identified in the human APOE gene. The protein structure depends on the 
genetic polymorphisms, in particular two SNPs, rs7412 (C/T) and rs429358 
(C/T), are responsible for the three major alleles: epsilon-2 (ε2),epsilon-3 
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(ε3) and epsilon-4 (ε4). Thus, because of the two copies of each gene 
present in human cells, there are six APOE genotypes: ε2/ε2, ε2/ε3, ε2/ε4, 
ε3/ε3, ε3/ε4, and ε4/ε4. They are responsible for three homozygous (ε2/ε2, 
ε3/ε3, and ε4/ε4) and three heterozygous (ε2/ε3, ε2/ε4, and ε3/ε4) 
genotypes [58]. The three APOE protein isoforms differ from each other by 
two cysteine/arginine interchanges at position 112 and 158. APOE2, 
APOE3, and APOE4 contain cysteine/cysteine, cysteine/arginine, and 
arginine/arginine at these two positions, respectively [59]. 
APOE plays a role in the transport and metabolism of triglyceride-
cholesterol. Genotyping could be used to improve the diagnosis of 
triglyceride cholesterol variants, and APOE polymorphisms were also 
associated with altered odds of having AD and other diseases. 
Determination of APOE level is of potential interest when studying different 
forms of brain damage and as a marker of ongoing regenerative processes 
in the brain.  
APOE isoform-specific effects on APOE/Aβ complex levels may mediate 
the increase in soluble Aβ levels that correlate with APOE4. Allelic 
variations in APOE were consistently associated with plasma 
concentrations of total cholesterol, LDL cholesterol, and APOB (the major 
protein of LDL, VLDL, and chylomicrons). APOE2 was studied in disorders 
associated with elevated cholesterol levels or lipid derangements such as 
type III HLP, coronary heart disease, stroke, peripheral artery disease, and 
diabetes mellitus [60]. But the ɛ2 allele is also associated with a lower risk 
of AD-related neurodegeneration [61], and with increased longevity in 
general [62]. APOE4 is a major genetic risk factor for neurodegenerative 
diseases such as AD and PD [63-65]. 
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1.2.1.1 APOE and Alzheimer's Disease 
Understanding structural differences in APOE isoforms helped establish the 
molecular mechanism responsible for the associated pathology. Defects in 
APOE could result in alterations in its structure and function [66]. The 
critical effect of APOE in regulating plasma lipid and lipoprotein levels has 
been extensively and carefully studied. In particular, focusing on the APOE 
role in transporting cholesterol in and out of the central nervous system 
(CNS). The distribution of APOE's major alleles, ε2, ε3, and ε4, in AD 
patients is 3.9%, 59.4%, and 36.7%, respectively [65]. Based on the strong 
association between APOE and Aβ in the brain [9], APOE was suggested 
as an Aβ-binding protein that induces a pathological β sheet conformational 
change in Aβ [10]. APOE4 suggests probably increases the risk of AD by 
initiating and accelerating Aβ accumulation, aggregation, and deposition in 
the brain. Genome-wide association studies have shown that the APOE4 
allele is associated with AD [67,68] and was detected in homogeneous and 
heterogeneous populations in North America, Europe, and Asia. 
It is estimated that the ε4 allele is the principal genetic factor in up to 50% 
of all cases of AD [69]. Moreover, risk for AD was increased two- to 
threefold in individuals who carried the heterozygous ε4 allele and about 
12-fold in those who carried the homozygous ε4 allele [69]. Instead, there 
was evidence suggesting that APOE2 allele may be protective against AD 
or associated with a marked reduction in AD risk [61]. AD risk in APOE 
ε2/ε2 or ε2/ε3 carriers was lower than in those carrying ε3/ε3 [70]. The 
APOE's role in AD is well established. Therefore, further studies are 
needed to understand the possible association between APOE and the rate 
of disease progression. APOE was classified as a risk factor for AD, but the 
molecular events that precede dementia remain elusive. APOE4 was 
suggested to be associated with damage of the vascular system in the 
brain, leading to AD pathogenesis. 
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1.2.2 Synaptosomal-Associated Protein of 25 kDa 
The Synaptosomal-Associated Protein of 25 kDa (SNAP-25) gene is 
located on chromosome 20p12-p11.2. It codes for a 206 amino acid 
presynaptic plasma membrane protein that is fundamental component of 
the SNARE (soluble N-ethylmaleimide-sensitive factor activating protein 
receptor) complex responsible for vesicle fusion and the regulation of 
synaptic vesicle exocytosis that are critical points in neurotransmission. It is 
a membrane bound protein anchored to the membranes of neurons via 
palmitoyl side chains located in the central region of the molecule, and 
together with syntaxin and the synaptic vesicle protein 
VAMP/synaptobrevin constitutes the initial SNARE docking complex for 
regulated exocytosis [71]. Besides its well characterized role in regulating 
exocytosis, there is increasing evidence that SNAP-25 interacts with a 
variety of other proteins involved in diverse functions; in particular it 
modulates various voltage gated ion channels [72] inhibiting their function 
and reducing responsiveness to depolarization [73,74]. 
Several studies demonstrate an association between SNAP-25 gene 
polymorphism as well as altered expression of the protein with personality 
disorders, schizophrenia, and attention deficit and hyperactivity disorder; 
these studies reported that the SNAP-25 gene might influence development 
of these disorders. Changes in SNAP-25 levels are present in 
schizophrenia, with levels of the protein being decreased in the 
hippocampus and the frontal lobe Broadman’s area (BA) 10, and increased 
in prefrontal lobe BA 9 and in the cingulate cortex [75] as well as in 
cerebrospinal fluid (CSF) [76]. A SNAP-25 promoter variant was also found 
to result in an augmented protein expression in the brain of patients with 
early onset bipolar disorders [77]. Higher levels of this protein have also 
been involved in attention deficit hyperactivity disorder [78], a condition 
characterized by hyperactive behavior and impaired attentive ability 
resulting in social dysfunction [79], and neuroticism [80]. In this case, the 
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observed association is between attention deficit hyperactivity disorder and 
two single nucleotide polymorphism (SNPs) localized between intron 3 and 
the 3’ untranslated region of SNAP-25 gene (rs3746544 and rs1051312) 
[81,82], whereas a third SNP (rs363043) correlates with hyperactive 
behavior in autistic children [83]. Notably, the SNAP-25 gene lies in an area 
linked to intelligence (20p12–p11.2) [84], and a family-based genetic 
association was reported between variation in intelligence quotient (IQ) 
phenotypes and two intronic variants on the SNAP-25 gene. This study 
shows that particular SNAP-25 SNPs (rs363043, rs353016, rs363039, 
rs363050) are associated with variation in Intelligence Quotient (IQ) 
phenotypes. These SNPs are localized within intron 1 in a region spanning 
about 13.8 kb, and are known to affect transcription factor binding sites 
[85]. SNAP-25 gene polymorphisms are so suggested to associate with 
both variations in IQ phenotypes and a number of neurologic conditions, 
including the age related decline of cognitive function [86]. 
More recent data demonstrated that SNAP-25 expression negatively 
correlates with MMSE scores, as higher CSF concentrations of SNAP-25 
were seen in patients suffering from more severe cognitive decline [87]. 
Notably: 1) an excess of SNAP-25 activity during adulthood was shown to 
be enough to mediate significant deficits in the memory formation process. 
2) Expression of SNAP-25 in the adult dorsal hippocampus was 
demonstrated to result in the dysregulation of memory consolidation 
machinery in this brain region [88] and 3) over expression of SNAP-25 in 
cultured hippocampal neurons associates with impaired synaptic 
transmission [89]. Altogether, these results suggest that increased SNAP-
25 levels do impair synaptic maturation and/or neurotransmission. 
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1.3 AIM 
The principal aim of this study is to verify a possible involvement of SNAP-
25 in Alzheimer's disease by comparing AD patients with age and gender-
matched healthy controls. In particular, the frequency of distribution of five 
SNAP-25 gene polymorphisms (rs363043, rs363039, rs363050, rs3746544, 
rs1051312) was correlated with the risk of AD development in elderly 
people and then replicated in MCI population. 
AIM 2: Correlation of SNAP-25 SNPs with cognitive decline: we correlated 
SNAP-25 polymorphisms with the degree of cognitive impairment evaluated 
with an extensive neuropsychological assessment. We considered a 
category fluency task as an indirect measure of long-term memory status 
allowing us to test verbal competences that rely on the structure of 
semantic network. Semantic fluency requires integrity of semantic 
concepts, and dysfunction occurs early in AD and causes significant 
disability with AD progression.  
AIM 3: Correlation of SNAP-25 SNPs and fMRI: Recently, evidences from 
neuropsychological [90,91] and functional magnetic resonance imaging 
(fMRI) studies [92-94] showed that language deficits, especially those 
interesting verbal fluency functioning, are precursors of AD clinical 
condition. Possible associations between SNAP-25 SNPs and fMRI 
parameters were analyzed in AD patients.  
AIM 4: Correlation of SNAP-25 SNPs and APOE with the rehabilitative 
outcome: As an effective pharmacological treatment for AD is still missing, 
the potential usefulness of non-pharmacological interventions in both 
preventing and slowing cognitive decline in AD [95] is actively investigated. 
Because genetic patterns have convincingly been shown to modulate the 
clinical severity of AD, we investigated whether any correlations could be 
detected between APOE4 positive/negative (APOE4+/-) and SNAP-25 
polymorphisms, and the outcome of rehabilitative treatment, in particular 
the MST therapy, in patients with mild-to-moderate AD. 
17 
 
CHAPTER II 
 
2. MATERIAL AND METHODS 
 
2.1 Subjects 
A total of 1680 Italians of Caucasian origin were enrolled; the study was 
designed as a case control comparing 607 patients, with diagnosis of 
probable or possible AD and 615 healthy controls (HC1). A replication 
study was conducted enrolling 148 patients with amnestic mild cognitive 
impairment (aMCI) and a second group of 310 HC (HC2); both HC1 and 
HC2 were age-and gender matched with the patients (Table 1). Patients 
were consecutively recruited by the Neurology Departments of the Don C. 
Gnocchi Foundation and of the Fondazione Ca’ Granda, IRCCS Ospedale 
Maggiore Policlinico in Milano. AD patients had a clinical diagnosis of 
probable AD in mild to moderate stage of disease according to the 
NINCDS-ADRDA Work Group criteria [96] and DSM IV-R [97]. Reversible 
causes of dementia were excluded after medical and neurological 
evaluation, laboratory analysis, CT scan or MRI, and other investigations 
when necessary (e.g., electroencephalography, single-photon emission 
computerized tomography scan, CSF examination, etc.); all AD cases were 
sporadic. Outpatients diagnosed with aMCI according to Petersen criteria 
[98] were consecutively recruited as well from those attending the Memory 
Disorders Outpatients Service of the Don Gnocchi Foundation. Only aMCI 
individuals considered at high risk to develop AD were enrolled in the study. 
To be eligible, aMCI subjects had to meet the following operational criteria: 
memory complaint, confirmed by an informant; abnormal memory function, 
documented by extensive neuropsychological evaluation; normal general 
cognitive function, as determined by both Clinical Dementia Rating (CDR) 
[99] scale (CDR with at least a 0.5 in the memory domain); no impairment 
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in functional activities of daily living as determined by a clinical interview 
with the patient and informant; no significant cerebral vascular disease 
(Hachinski score less than or equal to 4) [100]; no major psychiatric 
illnesses with particular attention to exclude subjects with history of 
depression (Hamilton Depression Rating Scale score less than or equal to 
12) [101,102]. 
Patients are followed with annual brain MRI and routine laboratory tests, 
and re-evaluated approximately every 6 months with neurological 
examination and a battery of neuropsychological tests and scales. Two 
groups of HC: HC1 and HC2 of unrelated Italians that were age- and 
gender-matched with AD and aMCI patients respectively were recruited as 
well. These individuals were selected according to the SENIEUR protocol 
for immuno-gerontological studies [103,104]; their cognitive status was 
assessed by Mini-Mental State Examination (MMSE) and mean raw data 
scores were reported in Table 1. All the individuals enrolled in the study, 
and their relatives when appropriate, provided written informed consent 
according to a protocol approved by a local ethics committee of the Don C. 
Gnocchi Foundation before admission to the study. 
 
2.2 Neuropsychological evaluation and psychometric assessment 
A randomly selected subgroup of 209 AD (72 males, 137 females) and 54 
aMCI (24 males, 30 females) individuals underwent extensive 
neuropsychological evaluation that included MMSE [105], language 
functions tests (phonological and categorical fluency [106] and Token tests 
[107]), short-term memory tests (Corsi, Digit Span Forward and Backward 
tests [108]), long term memory tests (Rey’s Figure Delayed Recall [108]; 
Paired-Associate Learning test, and Story Recall test [106]) and frontal-
executive functions (Raven Coloured Progressive Matrices [109]), visuo-
spatial abilities (Rey’s Figure Copy [108]). Categorical fluency impairment 
was also evaluated with fMRI verbal fluency task (the paced overt version 
19 
 
of verbal fluency paradigm described by Basho and colleagues [110], see 
data analysis section). All the evaluation values were adjusted for age and 
educational level (conversion formulae are reported in the appropriate 
references) and only the corrected scores were used for correlation 
analysis. 
 
2.3 Rehabilitation treatment  
 
2.3.1 Subjects 
A subgroup of fifty-eight patients (32 females /26 males, mean age 75.8 
years; SD=5.4 years) was enrolled, who underwent MST at the Neurology 
Departments of the Don Gnocchi Foundation. All patients had a clinical 
diagnosis of probable or possible AD with associated mild cerebrovascular 
disease in mild to moderate stage of progression according to the NINCDS-
ADRDA Work Group criteria [96]. Every patient was examined twice: at 
baseline and at the end of the 10 weeks treatment. 
 
2.3.2 Rehabilitative methods 
The MST program involves three different actors: persons with Alzheimer 
(PWA), the dyade PWA-caregiver and the caregiver him/herself. 
The MST program [50,111], involved 3 levels of treatment: 
Level 1: The PWA performed 30 rehabilitation sessions (2.5 hours a day, 3 
days a week, for a total of 10 weeks) in a room with materials necessary to 
carry out recreational–occupational activities of daily life. MST was 
administered by a psychologist and a rehabilitation therapist, both 
specialized in cognitive rehabilitation. Strong and tight interaction between 
participants and therapists was a crucial feature of the program. The 
treatment involved 4 steps: (a) Reality Orientation activities and cognitive 
exercises (about 45-minute); (b) physical activity (about 30-minute); (c) 
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occupational activities of daily living (about 30-minute); (d) recreational 
activities (about 45- minute). 
Level 2: All caregivers of PWA had a single support interview with a 
psychologist at the beginning and at the end of the training. In these 
moments, family caregivers could freely express their psychological 
sufferance and their practical difficulties. Caregivers also followed a 
standardized short group educational program with a rehabilitation therapist 
designed to focusing on several points: AD clinical picture, pathogenetic 
mechanism, pharmacological therapy and recent advances in research, 
coping with behavioral problems, as well as legal and social aspects. The 
second level was offered (a) to collect data about past preferences and 
personality of the PWA in order to integrate this information into the 
rehabilitation program; (b) to offer psychological support to the caregiver; 
and (c) to promote the detection of practical coping solutions. Moreover, 
during psychoeducational meetings, caregivers were trained by the 
therapist in order to continue the treatment at home. 
Level 3: All PWA subjects performed further stimulation at home: aerobic 
physical activity and specific but simple cognitive activities every day. This 
level was introduced to improve in the amount and intensity of the MST 
treatment and to favor a positive PWA–caregiver interaction at home. 
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2.3.3 Cognitive, Functional and Behavioral evaluation 
All the 58 patients treated with rehabilitative therapy underwent cognitive, 
functional and behavioral evaluation status by an experienced 
neuropsychologist blinded to the treatment status who used psychometric 
tests and scales. MMSE was used as an index of change in cognitive 
functions, and, for the purpose of this work, MMSE raw scores were 
adjusted for age and educational level (conversion formulae are reported in 
[105]); only corrected scores were counted for correlation analysis. The 
Functional Living Skills Assessment - FLSA- [112] was used as a measure 
of functional-performance; FLSA assesses performance in tasks of 
everyday life through direct observation of role playing. Finally, behavioral 
disturbances were assessed with the Neuropsychiatric Inventory scale - 
NPI - [ 113]. 
 
2.4 SNPs typing 
Genomic DNA was isolated from peripheral blood mononuclear cells by 
phenol-chloroform extraction. SNPs were typed using the Taqman SNP 
Genotyping Assays (Applied Biosystems by Life Technologies, Foster City, 
CA, USA) on an ABI PRISM 7000 Sequence Detection System. For 
rs363039, rs363043, rs363050 and rs3746544, respectively, the 
C_327976_10, C_2488346_10, C_329097_10, and C_27494002_10. 
Human Pre-Designed Assays (Applied Biosystems by Life Technologies) 
were used. The restriction enzyme polymorphism rs1051312 was 
genotyped by DdeI digestion as previously described [81]. 
 
2.5 APOE4 
Customer-designed Taqman probes for the 112 and 158 codons were 
used. Primers and probes for the 112 codon are: 112 Forward primer: 5'-
GGG CGC GGA CAT GGA G-3', 112 Reverse primer: 3'–TCC TCG GTG 
CTC TGG CC-5_, 112 Arg Probe : 5'-CGT GCG CGG CCG-3_-FAM, 112 
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Cys Probe: 5'-ACG TGT GCG GCC GCC TG-3'-VIC. Primers and probes 
for the 158 codon are: 158 Forward primer: 5'-TCC GCG ATG CCG ATG-
3', 158 Reverse primer: 3'-GCT CGG CGC CCT CG-5', 158 Arg probe: 5'-
CCT GCA GAA GCG CCT GGC A-3'-FAM, 158 Cys probe: 5'-CCT GCA 
GAA GGG CCT GGG AGT-3'-VIC. 
 
2.6 fMRI protocol and data analysis 
MRI scans were obtained using a 1.5 Tesla scanner (Magnetom Avanto, 
Siemens, Erlangen, Germany). Functional images were acquired with 
single-shot gradient echo EPI sequence (TR/TE = 3000/50 ms, voxel size = 
3.9×3.9×3mm3, 38 axial slices, 120 volumes) using blood oxygenation level 
dependent (BOLD) contrast. A morphological three-dimensional T1-
weighted MPRAGE sequence (TR/TE = 1900/3.37 ms, voxel size = 
1×1×1mm3, number of axial slices = 176) was also acquired to be used as 
anatomical scan for fMRI analysis. Thirty-eight subjects (28 AD patients 
and 10 HC) were selected to perform the paced overt version of verbal 
fluency paradigm (ABAB block design) [114]. Eighteen of these patients 
carried the rs363050 (AA or AG) and rs363043 (CT or TT) genotype (group 
1); the other 10 carried the rs363050 (GG) and rs363043 (CC) genotype 
(group 0). For each individual 6 semantic categories were randomly 
presented during the fMRI acquisition. Overt responses were obtained via 
an MRI-compatible patient response and sound system (VisuaStim Digital, 
Resonance Technology Inc.) The use of ePrime software (e-Prime 2.0 
Psychology Software Tool, http://www.pstnet.com) ensured exact timing of 
prompts. 
 
2.7 Statistical analysis 
Chi-square analysis was used to exclude any deviation of SNP genotype 
distribution from Hardy-Weinberg equilibrium (HWE) and to compare case-
control differences of SNPs distributions after gender stratification. 
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Haplotype analyses were performed using the SHEsis software freely 
available at http://202.120.7.14/analysis/myAnalysis.php [114,115]. 
The Kolmogorov-Smirnov (K-S) test was applied to verify normal 
distribution of numerical variable scores. Cognitive scores, which resulted 
normally distributed, were shown as mean and standard deviation (SD) and 
analysis of variance ANOVA was performed in relationship with SNPs 
distribution. For those variables, which were not normally distributed, 
Kruskall-Wallis test was applied. For genotype analyses pc values were 
corrected for 2 degree of freedom (degree of freedom of the genotype 
distribution of the three different genotypes); p values of allelic comparison 
have only 1 degree of freedom because they analyze biallelic 
polymorphisms, therefore they did not need to be corrected for degree of 
freedom. A multivariate logistic forward stepwise regression model 
corrected by gender and APOE4 positivity was used. This model had 
categorical fluency scores <25 or >25 as response variables in AD and in 
aMCI and genotype (rs363050 (AA/AG versus GG) and rs363043 (CT/TT 
versus CC)) as explanatory covariates, Post hoc power analysis were 
performed for all logistic regression and reported if the actual power was 
lower than 90%. Haplotype association analysis was performed using plink 
[116] by logistic regression; haplotype probabilities of individual subjects 
were incorporated as covariates in the regression model, which estimate 
the Odds ratios and p values associated with having a score of categorical 
fluency impairment ≤25, adjusting for gender and APOE4 positivity. 
Statistical analysis on fMRI data was performed using SPM8 (SPM8, 
http://www.fil.ion.ucl.ac.uk/spm). Preprocessing of functional images 
involved realignment, co-registration to the anatomical image, spatial 
normalization to the Montreal Neurological Institute (MNI) space, and 
spatial smoothing with a 8mm full-with at half-maximum (FWHM) Gaussian 
kernel. Single subjects statistical analysis was then performed with general 
linear model (GLM) approach [117] to detect the activation areas during the 
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task (t-contrast: categorical fluency A versus control condition B). The 
contrast images obtained at the single-subject level were used to compute 
the second level analyses. An ANOVA full factorial design was employed 
with a 3 level factor to model the groups (AD gr0, AD gr1, and HC), and 
with task performance, intracranial volume (ICV) (obtained by adding up 
white matter volume + grey matter volume + CSF volume) and MMSE 
scores as nuisance covariates, to adjust for potential confounds. We used a 
t-Student’s contrast to assess the main effect of categorical fluency versus 
control condition in HC and AD (both gr0 and gr1) and to describe the 
difference among the genotypes (HC versus AD gr0; HC versus AD gr1; 
AD gr0 versus AD gr1). The maps resulting from the second level analyses 
were thresholded with two approaches: first, the activation clusters that 
survived after correction for multiple comparisons (Family wise correction, 
pFWE-corr <0.05) and an extent threshold of voxel size of 10 adjacent 
voxels were considered; then, for exploratory purposes, group differences 
were also described considering an uncorrected p< 0.001 threshold with 50 
or more contiguous voxels. The contrast maps (one for each subject) 
entered in a second level analysis (ANOVA). ANOVA was performed to 
describe the difference among the three groups (HC, group 0, Group 1). 
Only activation clusters that survived after correction for multiple 
comparisons (Family wise correction, pFWE-corr <0.05) and an extent 
threshold of voxel size of 10 adjacent voxels were considered in the results 
section. Task performance entered the fMRI second level statistical 
analyses as a covariate due to the different performance obtained from AD 
(99%) and HC (78%). 
The Kolmogorov-Smirnov (K-S) test was applied also to verify normal 
distribution of numerical variable scores resulted by the group of 58 
patients whom underwent rehabilitative MST therapy. All numerical scores, 
resulted normally distributed, and they were shown as mean and standard 
deviation (SD) and linear regression analysis was performed between 
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mean delta score of MMSE, NPI, FLSA evaluations after rehabilitative 
treatment and age, age of disease onset, disease duration, level of 
education and mean baseline score of each scale. ANOVA calculation was 
performed to analyse gender association with MMSE, NPI and FLSA delta 
scores. A multivariate logistic forward stepwise regression model was 
computed using APOE4+ vs. APOE4- as response variables and difference 
between scores evaluated after rehabilitative treatment and at baseline (∆) 
of MMSE, NPI and FLSA scales as explanatory variables. Moreover, this 
model was corrected by MMSE at baseline (MMSEb), NPIb and FLSAb 
values, age of patients at the baseline, their level of education and gender 
Similarly a multinomial, multivariate logistic regression analysis was 
performed evaluating each SNAP-25 polymorphic genotype as responsible 
variable and ∆MMSE, ∆NPI and ∆FLSA as explanatory variables, together 
with MMSEb, NPIb and FLSAb values, age of patients at the baseline, their 
level of education, gender and APOE4+ genotype which were considered 
as covariates. Haplotype association analysis was performed using plink 
software [116] by logistic regression analysis; haplotype probabilities of 
individual subjects were incorporated as covariates in the regression 
model, which estimate the Beta value associated with ∆MMSE, ∆NPI and 
∆FLSA. 
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CHAPTER III 
 
3. RESULTS 
 
3.1 SNAP-25 polymorphisms distribution 
The five SNAP-25 gene SNPs were in Hardy Weinberg equilibrium in 
patients and controls, as shown by molecular genotyping. Genotype and 
allelic distribution comparisons revealed the presence of a significant 
association between rs363050 (AA) and AD (pc = 0.002, OR:1.47) (Table 
2a). Allelic distribution analyses confirmed that the rs363050 (A) allele is 
more frequently present in AD patients compared to HC1 (p = 0.01, 
OR:1.24) and showed that the rs363043 (T) allele is statistically more 
frequent as well in AD than in HC1 (p = 0.01, OR:1.29). After stratification 
for gender, the rs363050 (AA) genotype and (A) allele resulted to be 
statistically more frequent in AD female patients compared to HC1 of the 
same gender (pc = 0.001, OR:1.64 and p = 0.0003, OR:1.46 respectively). 
Similarly, the rs363043 (T) allele was statistically more frequent in female 
AD patients than in controls (p = 0.02, OR:1.29). No significant differences 
were seen in males, possibly because of the lower analyzed numbers 
(Table 2a). The rs363050 (A) allele and the rs363043 (T) allele were also 
significantly associated with aMCI when these patients were compared with 
HC2 (p = 0.01, OR:1.42 and p = 0.04, OR:1.35) (Table 2b). Because the 
replication cohorts of aMCI and controls were relatively small (148 versus 
310), the post hoc power of the OR estimate (H0 OR= 1) was calculated. 
Considering the size of the cohorts, an OR point estimate of 1.39 and 
frequencies of 34.9 and 28% respectively, the actual power was 0.814, 
indicating that the number of the study population is sufficient for a case-
control study. The ε4 allele of APOE4 is the only known confirmed genetic 
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risk factor for sporadic AD. All the individuals were thus genotyped for 
APOE4 polymorphism and, as expected, results confirmed the presence of 
a positive association between APOE4 and both AD (p < 0.001, OR: 3.78 
versus HC1) and aMCI (p < 0.001, OR: 2.00 versus HC2) (Table 1). SNAP-
25 genotypes were equally distributed in APOE4+ and APOE4- individuals, 
indicating that SNAP-25 SNPs correlate with AD and aMCI independently 
of APOE4 (data not shown). Haplotype analysis of SNAP-25 SNPs 
evidenced a linkage disequilibrium between rs363050 and rs363043 and 
between rs3746544 and rs1051312 (Figure 1), with the rs363050/rs363043 
A-T haplotype being statistically more frequent in AD compared to HC (p = 
0.002, OR: 1.45) and in aMCI compared to HC2 (p = 0.03, OR: 1.35). 
Finally no association was detected between the SNAP-25 SNPs 
(rs363039 (G/A), rs3746544 (T/G), and rs1051312 (T/C)) and either AD or 
aMCI. 
 
3.2 SNAP-25 polymorphisms and neuropsychological evaluation 
Because the results above suggest an association between SNAP-25 
genotypes and both AD and aMCI independently of APOE4, we verified 
possible correlations between such genotypes and AD-associated clinical 
parameters in a randomly selected subset of 209 AD and 54 aMCI patients. 
ANOVA analysis regarding categorical fluency scores showed that the 
rs363050 and rs363043 genotypes resulted as pathological (≤25) in AD 
(df:2, F = 4.65, p = 0.01 and df:2, F = 3.85, p = 0.03, respectively) (Table 
3). Further supporting the importance of these SNPs in modulation of 
categorical fluency, data indicated that the cognitive skewing between 
pathological and normal value score increased when AD were stratified 
according to the presence/absence of the rs363050 (A) and rs363043 (T) 
alleles. Therefore lower categorical fluency scores were detected in 
patients carrying the rs363050 (A) allele in either homozygote rs363050 
(AA) or heterozygote (AG) compared to those carrying rs363050 (GG) 
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(df:1, F = 9.52, p = 0.002 and df:1, F = 7.54, p = 0.01). Similarly, reduced 
categorical fluency scores were seen in rs363043 (TT) homozygote AD 
patients compared to those carrying the rs363043 (CC) genotype (df:1, F = 
5.36, p = 0.02). Notably, the skewing of categorical fluency scores was 
lower in patients carrying the rs363043 (CT) heterozygous pattern 
compared to those carrying the rs363043 (CC) genotype (df:1, F = 3.75, p 
= 0.05) (Table 3). Finally, no correlations were detected between SNAP-25 
genotypes and categorical fluency scores in aMCI, in whom such scores 
were above the 25 points cut-off. The relative contribution of rs363050 
(AA/AG) versus rs363050 (GG) and of rs363043 (TT/CT) versus rs363043 
(CC) in the model was evaluated next in a multivariate binary logistic 
regression model taking in account APOE4 positivity and gender as 
covariates. Categorical fluency scores ≤25 or >25 were adopted as the 
response variable; SNAP-25 genotypes, APOE4+/APOE4- and gender as 
covariates. Stepwise binary logistic regression analysis evidenced that both 
rs363050 (AA/AG) and rs363043 (TT/CT) are statistically correlated to 
categorical fluency impairment when they are inserted singularly in 
regression analysis and adjusted for APOE4 and gender (rs363050 
(AA/AG) p = 0.005; OR: 3.93) (Table 4; Model 1); (rs363043 (TT/CT) p = 
0.04 OR: 1.82) (Table 4; Model 2). When both these variables and their 
interaction were evaluated in the same model, rs363050 (AA/AG) alone 
remained associated to categorical fluency impairment (p = 0.01 OR: 
3.167). These results suggest that, even if both rs363050 (A) and rs363043 
(T) alleles correlate with categorical fluency impairment, the involvement of 
rs363050 (A) is stronger than the one of rs363043 (T). Therefore, when 
analyzed together, one masks the other. Finally, logistic regression analysis 
was performed using the Plink software to evaluate haplotype distribution in 
relationship with categorical fluency impairment (≤25 or >25) and adjusting 
for gender and APOE4 positivity. Results confirmed that the 
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rs363050/rs363043 A-T haplotype is significantly associated with lower 
categorical fluency scores (p = 0.03 OR: 1.25) (Table 5). 
 
3.3 SNAP-25 and functional MRI 
A group of AD patients and HC1 underwent fMRI evaluation to verify the 
possible correlations between SNAP-25 genotypes and imaging patterns. 
We analyzed 10 HC1, 18 AD patients in whom the SNAP-25 SNPs being 
more frequent in AD were present (group 1), and 10 AD patients in whom 
the SNAP-25 SNPs being more frequent in AD were NOT present (group 
0). After discarding 4 patients (3 out of group 1 and 1 to out of group 0) for 
excessive motion artifacts, significant differences (ANOVA p < 0.001) 
emerged. As expected, the Bonferroni-corrected ANOVA results indicated 
that task performance was significantly better in HC1 (mean task 
performance 99.24%±1.07%) compared to AD patients (mean group 0: 
76.37%±12.91%, p = 0.002; mean group 1 : 80.14%±4.37%, p < 0.001); no 
significant differences were found between the two AD groups. 
Demographical, neuropsychological and behavioral task-fMRI 
characteristics were shown in Table 6.  Imaging results for category-driven 
word generation showed an activation in the bilateral (left > right) frontal 
cortex (inferior and middle frontal gyri), the left premotor cortex, the bilateral 
cingulate gyrus, the medial temporal lobe cortex, and the basal ganglia in 
HC1. The overall pattern of brain activation seen in AD was similar to that 
seen in HC1, even if a significantly reduced recruitment was detected in the 
frontal cortex (Figure 2A, B). Raising the statistical threshold to an 
uncorrected level for statistical purposes (punc <0.001), we noticed in AD 
patient compared to HC a significant hypoactivation also in temporal cortex 
(temporal pole and the fusiform gyrus). Nevertheless, direct comparison 
between the two AD groups (ANOVA) showed significant differences (pFWE-
corr <0.05 at cluster level).  
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Thus, brain activity was significantly reduced in group 1 patients in the 
cingulate cortex and in the frontal (middle and superior gyri) and the 
temporo-parietal (angular gyrus) area (Figure 2C); in the opposite 
comparison (group 1 > group 0) increased activation was not detected in 
any of the brain regions involved in the task. 
 
3.4 Rehabilitation results 
Neuropsychological evaluations were performed at baseline and at the end 
of the 10 weeks treatment. Differences between the results obtained at 10 
weeks and at baseline are reported as Delta scores (ΔMMSE, ΔNPI, 
ΔFLSA). Improvement are represented by ΔMMSE and ΔFLSA>0, whereas 
a behavioural improvement is described by ΔNPI <0. Results of correlation 
analyses between ΔMMSE, ΔNPI and ΔFLSA values and demographic 
factors, calculated by linear regression analysis considering the baseline 
value of each scale as covariate, are presented in Table 7. 
A significant association between ΔMMSE values and gender (female vs. 
male) (negative Beta value of association to females: pc=0.02 Beta=-0.33) 
was found together with a borderline significant positive correlation 
between MMSE values and  age at baseline  (pc=0.05; Beta= +0.25).  
Results also showed that NPI outcomes were negatively associated with  
the level of education (pc=0.02; Beta:-0.31). In contrast, no correlations 
were found between cognitive and behavioral outcomes after treatment, 
and disease duration, age at baseline and age at onset. 
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3.4.1 APOE genotypes 
A total of 27 out of the 58 patients carried the APOE4 allele, (APOE4+): 4 
were homozygous E4+/E4+ and 23 were heterozygous E4+/E3+. Among 
APOE4- subjects: 4 carried E2+/E3+ genotype and 27 were E3+/E3+. 
Binomial logistic regression analysis was performed to calculate possible 
association between APOE polymorphisms and ΔMMSE, ΔNPI and ΔFLSA 
scores. APOE4+ and APOE4- allelic association with Δvalues for each 
scale was calculated after correction for baseline values, age, level of 
education and gender, which were considered as covariates. Results 
indicated the presence of a statistical association between APOE 
polymorphism and ΔMMSE scores after treatment (pc=0.041).Therefore, a 
weak positive effect of the APOE4- allele (OR: 1.4; 95%CI:1.0-1.9) on the 
outcome of MST was observed (ΔMMSE= 2.0±1.9) whereas the APOE4+ 
allele was correlated with lower MMSE scores after therapy (ΔMMSE= 
0.5±2.5). Graphical results are shown in Figure 3. No associations were 
observed between APOE polymorphisms and either ΔNPI or ΔFLSA 
results. 
 
3.4.2 SNAP-25 genotypes 
Frequency of distribution of the three analyzed single nucleotide 
polymorphisms (SNPs) of the SNAP-25 gene (rs363043(C/T), 
rs363039(G/A), rs363050(A/G)), was evaluated next by multinomial logistic 
regression analysis in relationship with ΔMMSE, ΔNPI and ΔFLSA scores. 
SNAP-25 genotypes categories for each SNP were considered as the 
dependent variable, and possible associations with the Δ values were 
calculated after correction for the baseline value, age, level of education, 
gender and APOE genotype (E4- vs. E4+), which were considered  as 
covariates.  
A statistically significant association was observed between ΔNPI values 
and the rs363050 and rs363039 SNAP-25 genotypes (Figure 4 panel B, 
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Figure 5 panel E). In particular, subjects carrying the rs363050(G) as well 
as the rs363039(A) alleles were characterized by lower ΔNPI scores, which 
correspond to an improvement in behavioural functions after rehabilitative 
treatment. Notably, a significantly better outcome after treatment was 
observed in individuals carrying the minor rs363050 homozygote 
(GG)(ΔNPI = -2.4 ± 3.1) compared to those with the major homozygote 
(AA) genotype (ΔNPI = -0.1 ± 3.0)(pc=0.015: OR: 6.6, 95%CI: 1.4-30.6), 
and in those with the heterozygote (AG)(ΔNPI = -2.7 ± 2.9) compared to 
those with the homozygote (AA)(ΔNPI = -0.7 ± 0.9) genotype (pc=0.007, 
OR: 1.83, 95%CI:1.2-2.8)(Figure 4 panel B). A similar significantly better 
outcome was observed in subjects carrying the rs363039 minor 
homozygote (AA)( ΔNPI = -2.9 ± 3.1) compared to those with the major 
homozygote (GG) genotype (ΔNPI = -0.5 ± 3.2)(pc= 0.019, OR: 10.8 
95%CI: 1.5-78.2) and in (AA) homozygous (ΔNPI = -2.7 ± 2.2) compared to 
(AG) heterozygous individuals (ΔNPI = -1.5 ± 2.9) (pc=0.025; OR: 9.6, 
95%CI: 1.3-69.8)(Figure 5 panel E).  
 
3.4.3 Haplotype analysis 
The detection of a linkage disequilibrium between rs363050, rs363039 and 
rs363043 SNPs in intron 1 (figure 1) suggested us to further analyze 
possible associations between this haplotype and MST outcomes. Results 
showed the presence of a significant association between SNAP-25 
haplotypes and lower ΔNPI. In particular the rs363050(G)-rs363039(A)-
rs363043(C)-(GAC) haplotype was statistically associated with a better 
outcome of treatment as measured by the NPI scale (p=0.03, Beta value= -
1.27)(Table 8). 
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CHAPTER IV 
4. DISCUSSION 
 
SNAP-25 is a vesicular SNARE protein that plays an important role in the 
release of neurotransmitters via its interaction with voltage-gated calcium 
channels. SNAP-25 gene polymorphisms are suggested to associate with 
both variations in IQ phenotypes and a number of neurologic conditions, 
including the age-related decline of cognitive function [86]. Because 
anatomical and functional synapsis alterations are present in AD we 
evaluated the possible involvement of SNAP-25 polymorphisms in this 
disease. SNAP-25 is a highly polymorphic gene as it includes 225 SNPs. 
We focused on those that had previously been shown to correlate with 
human diseases and variations in intelligence and that localize within intron 
1, in a region spanning about 13.8 kb known to affect transcription factor 
binding sites [85]. Results herein suggest that SNAP-25 gene 
polymorphism associate with AD and aMCI in Italian patients. Thus, the 
frequency of carriers of the SNAP-25 rs363050 (A)(AA/AG) and the 
rs363043 (T)(TT/CT) alleles was significantly increased in AD and in aMCI 
compared with gender- and age-matched healthy controls. Notably, a 
declining degree of prevalence of these alleles was present when AD 
(higher prevalence) were compared to aMCI (intermediate prevalence) and 
HC (lower prevalence);  this observation is possibly due to the fact that not 
all aMCI will evolve into AD. It will be interesting to evaluate how many 
aMCI carrying the above-mentioned SNAP-25 genotypes will indeed 
develop AD. As a result of the SNAP-25 allelic distribution, the 
rs363050/rs363043 A-T SNAP-25 haplotype was statistically more frequent 
in both AD and aMCI compared to HC. These two SNPs are in linkage 
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disequilibrium, therefore their contribution may be due either to the fact that 
the rs363050 (A) genotype drags the rs363043 (T) genotype, or to the 
possibility that other genotypes within the haplotype are associated to AD 
development. Having observed a possible association between particular 
SNAP-25 SNPs, AD, and aMCI, we next verified the presence of 
correlations between such SNPs and clinical parameters. Results showed 
that the SNAP-25 haplotypes more frequently seen in AD, are associated 
with altered scores at the categorical fluency test. In particular, pathological 
mean scores in this test (≤25) were associated with the rs363050 (AA/AG) 
and rs363043 (CT/TT) alleles in AD, with the strongest association being 
seen with rs363050 (AA/AG). These alterations were present in AD alone, 
as in aMCI, scores were higher than the pathological cut off of 25. Results 
were analyzed next taking into account gender and APOE4 positivity by 
performing stratified analysis of different SNAP-25 polymorphisms in 
relationship with gender and with APOE4 positivity. Results indicated that 
the SNAP-25 SNPs-associated categorical fluency impairment is 
independent of both APOE4 and gender. Results of further multivariate 
logistic stepwise regression showed that, although both the rs363050 (A) 
and rs363043 (T) allele are associated with categorical fluency impairment, 
the role played by rs363050 (A) is stronger than that of rs363043 (T). 
Verbal fluency, and in particular Category fluency, is altered in AD [90,91], 
and a category fluency task is incorporated in the CERAD (Consortium to 
Establish a Registry for Alzheimer’s Disease) protocol for the diagnosis and 
the clinical staging of AD [118,119]. Category fluency relies on the structure 
of the semantic network, on the availability of sound lexical-semantic 
representations, and on the access to semantic knowledge, three facets of 
cognition that are affected in AD [90,91]. It seems thus biologically relevant 
that data herein suggest that impairments of these key components of 
language functioning are associated with the SNAP-25 SNPs that prevail in 
AD patients. Possible anatomical relationships between SNAP-25 SNPs 
35 
 
and categorical fluency impairment were finally analyzed by fMRI in a 
subset of AD patients. We adopted the verbal fluency paradigm described 
by Basho and colleagues [110] to test language function. This fMRI task 
was chosen because it allows an appropriate response monitoring and a 
tight control over and reduced individual variability of task performance, 
making it suitable for the application in patients with cognitive deficits. 
Results showed that brain activation and brain area recruitment (prefrontal 
regions, parieto-temporal area, and cingulate cortex) are significantly 
diminished in patients carrying the SNAP-25 SNPs that are more frequent 
in AD and correlate with pathological categorical fluency scores. This 
activation pattern could reflects pathologic alterations within critical nodes 
of the neural networks subserving working memory and attentional–
executive functions [120,121]. Recent studies have shown a relationship 
between reduced neural metabolism and poor performances in semantic 
memory tasks [94,122,123]. Our results are in line with these works, and 
especially with those focusing on the left temporo-parietal and left prefrontal 
cortex [121,122]. The most impaired areas we found in AD were the frontal 
cortex and the anterior cingulated. It is proven that damage in these areas 
could reasonably influence the efficiency of attentive processing in task 
accomplishment. Finally, though at lower levels of significance, AD patients 
presented a hypoactivation also in temporal pole cortex, an area that is 
commonly considered as integral part of the semantic network [124]. and 
fusiform gyrus. Interestingly, the impairment in the fusiform gyrus, an area 
that mediates between lateral semantic memory and medial episodic 
memory encoding networks, is coherent with recent evidence [125] 
showing that impairment in frontal and temporal areas involved in language 
network characterize the clinical evolution of AD. Brain activation 
impairments were significantly more frequent in AD patients carrying the 
rs363050 (AA/AG) and/or rs363043 (CT/TT) genotypes, and, on the other 
hand, an augmented brain activity was seen in bilateral parietal and frontal 
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brain area and in the cingulate cortex of AD patients carrying the rs363050 
(GG) and/or rs363043 (CC) compared to those carrying the rs363050 
(AA/AG) and/or rs363043 (CT/TT) genotypes. The higher activation of 
group 0 could be attributable to some sort of residual compensatory 
mechanisms in frontal areas that accounts for a semantic deficit [126]. 
Interestingly, the left inferior parietal lobe and angular gyrus are considered 
to be crucial areas in the processing hierarchy underlying concept retrieval 
and conceptual integration. A damage of the left angular gyrus is 
responsible for a variety of cognitive impairments, such as, among others, 
anomia, sentence comprehension impairment and dementia [127]. Notably, 
our AD patients did not show differences in activations of bilateral anterior 
temporal lobe (ATL) and TP. This lack of activation in ATL and TP can be 
read as a index of impairment of these areas that reflects a connective 
degeneration in temporal cortices in AD. Coherent with present results are 
recent findings on AD population [125] that show a decrease in 
neuroplasticity of temporal lobes with the progression of the disease. 
Categorical verbal fluency tests assess medial temporal lobe function [92] 
and are positively correlated with neurobiological hippocampal and parietal 
lobe neurochemical abnormalities in AD [128]. The SNAP-25 gene is highly 
expressed in the hippocampus [129], a brain structure that plays a crucial 
role in semantic fluency performance [130]. Animal studies showed that the 
hippocampal SNAP-25 protein is involved in memory consolidation and 
long-term memory formation in rats [131,132]; additional results indicate 
that changes of hippocampal SNAP-25 expression contribute to age-related 
decline of cognitive function [86]. It is therefore tempting to speculate that 
the SNPs described herein could influence the neuronal density and 
connectivity of the hippocampus, modulating synaptic plasticity and 
neurogenesis in the left hippocampus. Both the SNPs described herein, 
rs363050 (A/G) and rs363043 (C/T), localize within intron 1 in a region 
spanning about 13.8 kb which could affect transcription factor binding sites 
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[85]. We analyzed the functional effect, of rs363050 and 363043 SNPs on 
transcriptional activity using luciferase a reporter gene assay. Our 
preliminary results showed that the rs363050 (A) allele associates with a 
significantly higher SNAP-25 expression compared to the rs363050 (G) 
allele [133]. This could be due to the impairment of binding of factors 
involved in the modulation of the SNAP-25 gene expression level or to the 
binding of other factors, different from the ones that recognize the 
sequence of the parental allele, acting as repressor. Both reduced and 
excessive SNAP-25 activity has been implicated in various disease states 
that involve cognitive dysfunctions such as attention deficit hyperactivity 
disorder, schizophrenia, and AD [81,134-137]. An excess of SNAP-25 
activity during adulthood was shown to be sufficient to mediate significant 
deficits in the memory formation process.  
 
As previously described, AD is a highly prevalent neurodegenerative 
disorder with a complex and unclear pathogenesis; pharmacological 
therapies for AD are not yet available, and the efficacy of physical and 
occupational treatments is greatly variable amongst patients. As widely 
demonstrated, genetic factors play a role in the pathogenesis of AD. Thus, 
besides the presence of the E4 allele of APOE gene, the only known 
confirmed genetic risk factor for sporadic AD, SNPs in various genes, 
including interleukin-10, PIN-1 [138,139] and SNAP-25, have been shown 
to correlate with susceptibility to disease and to the rate of clinical 
progression. A further step of our research was to explore whether the 
outcome of multidimensional stimulation, including CS, in AD could be 
associated as well with the genetic background of the patient, focusing on 
APOE4 and SNAP-25 polymorphisms. Data herein suggest that this is 
indeed the case as significant associations were detected between such 
polymorphisms and the effect of rehabilitation.  
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Higher MMSE scores after rehabilitation were detected in APOE4- 
compared to APOE4+ patients, though at a low level of significance and 
SNAP-25 alleles and genotypes correlated with a significantly better 
outcome as measured by the NPI scale. These data are in agreement with 
recently published evidences indicating a poorer efficacy of Cognitive 
Stimulation on visuospatial memory performance measured using the Corsi 
test. [140] in APOE4+ patients. The APOE4 status has been reported to 
influence cognitive functions [141], possibly because APOE gene produces 
a protein that plays an important role in neuronal plasticity and repair [142-
144]. Thus, the APOE lipoprotein stimulates synapse development [145], 
clearance of lipid debris [146], and promotion of granule cell mossy fiber 
sprouting [147]. The effectiveness of these processes is reduced when the 
E4+ allele directs APOE production. Data in the animal model reinforce the 
idea that APOE alleles are involved in AD. Thus, a more efficient 
degradation of APOE4 in astrocytes in transgenic animals results in lower 
levels of APOE in the brain and CSF, suggesting that the reduced levels of 
total APOE seen in APOE4 carriers may directly contribute to disease 
progression. APOE4+ is also less efficient than APOE4- in transporting 
brain cholesterol [65]. Other data show that APOE polymorphisms modify 
neuroinflammatory responses, and influence both outcome from acute 
brain injury and the risk of developing neurodegenerative disease. 
Traumatic brain injury (TBI) accelerates neurodegenerative pathology in 
double-transgenic mice expressing the human APOE alleles and mutated 
amyloid precursor protein: this pathology is exacerbated in the presence of 
the APOE4 allele and the administration of an APOE-mimetic peptide 
markedly reduces the development of neurodegenerative pathology in 
these animals [142]. Very recently an increase of amyloid accumulation and 
allele frequency of APOE4 was seen in the mild TBI patients with cognitive 
impairment [148,149], and a meta-analysis concluded that the APOE4 
allele may be associated with a poor prognosis in severe TBI patients [150]. 
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These evidences suggest an APOE4 cognitive phenotype associated with 
more inefficient mechanisms of neuronal repair and plasticity. It is therefore 
possible that people with AD carrying APOE4 are less able to engage 
cognitive reserve mechanisms that could benefit from CS, with the result 
that carriers and non-carriers benefit differently from experiences that 
enhance cognition. A low level of significance was revealed in our 
evaluation of APOE4 involvement in MST outcome. This may be 
considered as a point of criticism, but it is nevertheless important because 
we cannot exclude APOE4 as covariate when involvement of other genetic 
marker as SNAP-25 has been evaluated in MST outcome.  
Polymorphisms in the SNAP-25 gene were instead mostly correlated with 
results at MST when behavioural improvement was measured. Thus, the 
SNAP-25 rs363050(G) and rs363039(A) alleles, as well as the SNAP-25 
rs363050(G)-rs363039(A)-rs363043(C) (GAC) haplotype, which are in 
linkage disequilibrium, were statistically associated with lower NPI scores 
after treatment, i.e. with a more relevant effect of this treatment of 
behavioural parameters. As we have suggested in the first part of the 
research, a role for SNAP-25 polymorphism in the risk of developing AD in 
individuals with a diagnosis of mild cognitive impairment (MCI), in 
particular, we have shown that the complementary rs363050(A) allele is 
significantly more frequent in patients with AD and MCI and is associated 
with pathological scores of categorical fluency and functional MRI 
parameters in individuals with a diagnosis of full-blown AD [151]. 
Previous studies suggested that synaptic loss correlates with the clinical 
manifestations of AD, while there is no relation between the number of 
accumulated parenchymal amyloid plaques and synaptic pathology 
[152,153]. More recent data demonstrated that SNAP-25 expression 
negatively correlates with MMSE scores, as higher CSF concentrations of 
SNAP-25 were seen in patients suffering from more severe cognitive 
decline [87]. Notably: 1) an excess of SNAP-25 activity during adulthood 
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was shown to be enough to mediate significant deficits in the memory 
formation process. 2) Expression of SNAP-25 in the adult dorsal 
hippocampus was demonstrated to result in the dysregulation of memory 
consolidation machinery in this brain region [88] and 3) over expression of 
SNAP-25 in cultured hippocampal neurons associates with impaired 
synaptic transmission [89]. Altogether, these results suggest that increased 
SNAP-25 levels do impair synaptic maturation and/or neurotransmission. 
These data thus suggest that, in AD patients, the lower success of 
rehabilitation seen in the presence of the rs363050(A) allele, or of a SNAP-
25 pattern in linkage disequilibrium with this allele, is the result of the higher 
SNAP-25 levels present in these patients.  
It has been assumed that AD progression and functional restoration 
depend on the capacity for neural plasticity within residual neural tissues; 
such plasticity was recently suggested to be at least in part influenced by 
polymorphisms in several genes known to orchestrate this process [154]. 
Both APOE and SNAP-25 proteins play important roles in neuronal 
plasticity and repair; data herein suggest that SNPs in these genes are 
correlated with the outcome of non-pharmacological treatment in AD.  
The promise of genomic medicine is to realize and to deliver a personalized 
approach to pharmacological and non-pharmacological treatment of 
diseases that is targeted to individual genetic pattern. Analysis of the 
genetic background of persons with AD could become useful in guiding the 
clinicians to define which rehabilitative intervention might better fit each 
patient, for example defining a more intensive or different kind of therapy in 
those subjects with a lower opportunity of success. The data presented 
here could, possibly in the near future, help in the optimization of the 
clinical management of individuals with neurological conditions. 
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CONCLUSION 
Results herein suggest that SNAP-25 gene polymorphisms (rs363050(A) 
and the rs363043(T) alleles as well as rs363050/rs363043 A-T haplotype) 
may be considered genetic risk factor for the development of AD and aMCI 
in Italian elderly people. The SNAP-25 rs363050(AA/AG) and 
rs363043(TT/CT) genotypes are associated with altered scores at the 
categorical fluency test. Correlations between SNAP-25 rs363050 (AA/AG) 
and/or rs363043 (CT/TT) genotypes and imaging patterns shown a 
significantly decreased brain activity in the cingulate cortex and in the 
frontal (middle and superior gyri) and the temporo- parietal (angular gyrus) 
area, as measured by fMRI. 
Association between APOE4 and SNAP-25 with rehabilitation outcome was 
revealed. Higher MMSE scores after MST were detected in APOE4- 
compared to APOE4+ patients, as well as SNAP-25 rs363050(G)(GG) 
allele and genotypes correlated with a significantly better outcome as 
measured by the NPI scale. 
These data thus suggest a lower success of rehabilitation in AD patients 
carrying the rs363050(A) and APOE4+ alleles, maybe due to the lower 
neuroplasticity associated to these genotypes. 
The data presented provide important indication of possible biomarkers for 
the prognosis and course of AD, and could provide a useful indication for 
the definition of rehabilitative interventions targeted to the patient. 
The goal of genomic medicine is to realize and to deliver a personalized 
approach to pharmacological and non-pharmacological treatment of 
diseases that is targeted to individual genetic pattern. 
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FIGURES AND TABLES 
 
Table 1: Baseline characteristic of patients with a diagnosis of Alzheimer 
disease (AD) or amnestic mild cognitive impairment (aMCI); healthy 
controls (HC1 and HC2) are also included. 
APOE4+: positivity for epslion4 allele; SD: standard deviation;1 AD vs. HC1: 
p<0.001 OR: 3.78 IC(95%): 2.09-4.93; 2 aMCI vs. HC2: p<0.001 OR:2.00 
IC(95%): 1.30-3.08 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
   AD 
(N=607) 
   HC1 
(N= 615) 
  aMCI 
(N=148) 
  HC2 
(N= 310) 
Parameters      
Age (years) [Mean 
±SD] 
 76.7±8.2 72.0±6.9 76.8±7.8 69.9±6.3 
Range (years)  53-96 44-104 59-96 41-86 
Male %  32.3 31.7 46.0 44.7 
MMSE score 
[mean±SD] 
 18.2±6.5 27.1±3.1 25.2±1.3 27.2±2.8 
Formal education  
(years)[mean±SD] 
 8.0±4.1 8.1±3.8 7.7±3.4 7.9±3.9 
APOE4+ %  47.01 19.01. 36.52 22.22 
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Table 2a: Genotype and allele distribution of the rs363050 and rs363043 
SNAP-25 SNPs in Alzheimer’s disease (AD) patients and in age- and sex-
matched healthy controls (HC1). Only results obtained in females are 
shown in details, as no significant differences were observed in male 
patients. OR: Odds ratio; 95%CI: Interval of confidence. pc: p value 
corrected for two degree of freedom for genotype distribution. 
1pc: AD vs. HC1; 2pc: female AD patients vs. female HC1; 3pc: AD vs. HC1; 
4p AD vs. HC1; 5p: female AD vs. female HC1; 6pc: AD vs. HC1;7p: AD vs. 
HC1; 8p female AD vs. female HC1. 
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  AD   HC1     
SNAP-25  
Females 
(N=411) 
% 
Males+ 
Females 
(N=607)
% 
 Females 
(N=420) 
% 
Males+ 
Females 
(N=615)
% 
 p value OR;  95%CI 
rs363050          
Genotype
s 
A/A 46
2
 44
1
  34
2
 35
1
  
1
pc= 0.002 
2
pc= 0.001 
1.47;  1.16-
1.86 
1.64;  1.23-
2.20 
A/G 44 42
3
  50 50
3
  
3
pc= 0.008 
0.72;  0.57-
0.90 
G/G 10 14  15 15    
        
1
pc=0.003  
2
pc=0.04   
 
Alleles A 68
5
 65
4
  59
5
 60
4
   
4
1.24; 1.05-
1.47  
5
1.46;  
1.18-1.79 
 G 32 35  41 40   
4
0.80;  0.68-
0.95 
5
0.69 ; 
0.56-0.84 
        
4
p=0.01 ; 
5
p=0.0003
 
rs363043         
Genotype
s 
C/C 44 44  51 49    
C/T 44 43  41 41    
T/T 12 13
6
  8 9
6
  
6
pc=0.08 
1.49; 1.02 -
2.18 
         
6
pc=0.04  
Alleles C 66 65  71 70   
7
0.80;  0.67-
0.95 
8
0.78; 0.63-
0.96 
 T 34
8
 35
7
  29
8
 30
7
   
7
1.29; 1.05-
1.45 
8
1.29; 1.04-
1.59 
        
7
p=0.01;  
8
p=0.02
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Table 2b: Genotype and allele distribution of the rs363050 and rs363043 
SNAP-25 SNPs in amnestic Mild Cognitive Impairment (aMCI) patients and 
in age-and sex-matched healthy controls (HC2).OR: Odds ratio; 95%CI: 
Interval of confidence;. pc: p value corrected for two degree of freedom for 
genotype distribution. 1pc: aMCI vs. HC2; 2p: aMCI vs. HC2;3pc aMCI vs. 
HC2; 4p: aMCI vs. HC2;  
 
  aMCI  HC2    
SNAP-25  
Males+ 
Females 
(N=148) 
% 
 
 
Males+ 
Females 
(N=310) 
% 
 
 p value OR;  95%CI 
rs363050        
Genotypes 
A/A 39  30 
 
  
A/G 50  51 
 
  
G/G 11
1
  19
1
  
1
pc= 0.04 0.52;  0.28-0.94 
     
1
pc=0.04 
Alleles A 64
2
  60
2
 
 
 
2
1.42; 1.07-1.90 
 G 36  40 
 
 
2
0.70; 0.52-0.94 
     
 
2
p =0.01 
 
rs363043        
Genotypes 
C/C 43  49    
C/T 45  41    
T/T 12  9 
 
  
     
3
pc=0.09 
Alleles C 65  70   
4
0,73; 0,54-0,99 
 T 35
4
  30
4
 
 
 
4
1,35; 1,01-1,82 
     
 4
p=0.04;  
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Table 3 : Categorical Fluency and SNAP-25 polymorphisms in AD and 
aMCI patients. SD: standard deviation; df: degree of freedom; p: p value 
corrected for degree of freedom. 1AA vs. GG;  2AG vs GG;. 3CC vs. TT; 4CT 
vs. TT;  
 
 
  AD       aMCI     
SNAP-25  Mean N SD f df p 
 Mea
n 
N SD f df p 
rs363050               
Genotypes 
A/A 24.2
1
 110 8.3 
1
9.5 1 
0.00
2 
 33.3 20 8.7    
A/G 24.3
2
 74 8.9 
2
7.5 1 0.01  33.3 25 8.9    
G/G 29.7
1,2
 25 6.8     33.6 9 6.1    
 Total 24.9 209 8.5 4.65 2 0.01  33.4 54 8.3   n.s 
           
rs363043               
Genotypes 
C/C 26.7
3
 82 9.0 
3
5.4 1 0.02  34.7 27 7.9    
C/T 24.1
4
 97 8.4 
4
7.5 1 0.05  31.6 24 8.5    
T/T 25.5
3,4
 30 6.1     36.0 3 8.5    
 Total 24.9
3,4
 209 8.5 3.85 2 0.03  33.4 54 8.3   n.s 
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Table 4: Categorical Fluency and SNAP-25 polymorphisms in AD patients. 
Results of  multivariate stepwise logistic regression analysis. Responsible 
variable: Categorical Fluency Score categorized as <25 (pathological) or 
>25 (normal). OR: Odds ratio; 95%CI: Interval of confidence. 
 
Model 1: AD patients (N=209); covariates: APOE4+ (ε4/ε4 ε4/ε3 ε2/ε4), 
Gender (female vs. male), SNAP-25 rs363050 (AA/AG vs. GG) 
Model 2:  AD patients (N=209); covariates: APOE4+ (ε4/ε4 ε4/ε3 ε2/ε4), 
Gender (female vs. male), SNAP-25 rs363043 (TT/CT vs. CC) 
 
  wald p value OR 95%CI 
Model 1   2.16 0.141 0.804 0.60-1.07 
Selected Variables rs363050 (AA/AG ) 7.79 0.005   3.93 1.50-10.32 
Unselected Variables APOE4+  0.58    
Gender   0.45    
Model 2  2.82 0.093 0.74 0.52-1.05 
Selected Variables rs363043 (TT/CT) 4.33 0.04  1.82 1.04-3.18 
Unselected Variables APOE4
 
+  0.72   
Gender   0.60    
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Table 5: Logistic regression analysis by plink software adjusting for  gender 
and APOE4 positivity. Categorical  Fluency and SNAP-25 haplotype  
rs363050/rs363043 polymorphisms in AD patients. Responsible variable: 
Categorical Fluency Score categorized as ≤25 (pathological) or >25 
(normal); covariates: APOE4+ (ε4/ε4 ε4/ε3 ε2/ε4), Gender (female vs. male) 
OR: Odds ratio;  
 
 
 
 
 
 
SNP1 SNP2 haplotype wald p value OR 
 
rs363050  
 
rs363043 
AT 4.84 0.0278 1.25 
GC 1.95 0.163 0.87 
AC 0.562 0.454 0.923 
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Table 6: Demographical, neuropsychological and behavioral task-fMRI 
characteristics. 
Comparisons of MMSE and fMRI task variables between controls (HC) and 
patients with Alzheimer’s disease (AD) were all significant at P<0.001; Post 
Hoc Test 1HC vs AD gr0:p<0.05; 2HC vs AD gr1:p<0.05. 
AD gr1= patients carried the rs363050 (AA or AG) and rs363043 (CT or TT) 
genotype; AD gr0= patients carried the rs363050 (GG) and rs363043 (CC) 
genotype  
 
 
  
AD gr0 
(N=9) 
AD gr1 
(N=15) 
HC 
(N=10) 
  
Group 
Comparis
on 
 
Age (years)[Mean ±SD] 
  
75.56±5.85 
 
74.67±5.39 
 
70.80±3.85 
   
Range (years)  69-83 61-81 64-77    
Male %  44.4 33.3 40.0    
MMSE score [mean±SD]  19.37±3.24
1
 20.03±2.44
2
 28.31±1.8
1,2
   P<0.001 
Performance on fMRI task    
Accuracy  77.37±12.918
1
 80.14±4.378
2
 99.24±1.078
1,2
   P<0.001 
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Table 7: Linear regression analysis between mean delta score of MMSE, 
NPI and FLSA evaluations after rehabilitative treatment and demographic 
data of AD patients. SD: standard deviation ; pc: p value corrected for 
baseline values; *: Statistically significant p value. MMSE: Mini Mental 
Scale Evaluation; NPI: Neuropsychiatric Inventory scale; FLSA: Functional 
Living Skills Assessment; MMSEb : MMSE value  at baseline, NPIb : NPI 
value at baseline; FLSAb: FLSA value at baseline. 
 
 
Demographic data N =58 ΔMMSE ΔNPI     ΔFLSA 
  pc          Beta pc           Beta pc         Beta 
*Gender  female / male (N) 32/26 0.02*    -0.33       0.60        +0.07 0.59         -0.07 
*Age (mean±SD) 75,8±5.4 0.05*    +0.25 0.37        -0.11 0.89         +0.02 
Age at onset (mean±SD) 73,5±5,6 0.06    +0.25 0.56        -0.09 0.39         -0.12 
Disease duration               
(mean ±SD) 
2.2±2.7 0.62    +0.81 0.21        -0.22 0.06         +0.30 
*Level of education   
(mean±SD) 
8,0 ±3,5 0.76    -0.04 0.02*        -0.31 0.77         +0.04 
*MMSEb (mean±SD) 20.8±3.6 0.05*    -0.26 - - 
*NPIb (mean±SD)   9.8±7.1 - 0.02*         -0.30 - 
*FLSAb  (mean±SD) 99.1±16.2 - - 0.02*         -0.30 
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Table 8: Haplotype association between SNAP-25 rs363050, rs363039, 
rs363043 and ΔNPI values. *: Statistically significant p value. 
 
 
 
 
 
 
 
SNP1 SNP2 SNP3 haplotype Beta p value 
 
rs363050 
 
rs363039 
 
rs363043 
AAT 0.64 0.69 
AGT 0.78 0.24 
GAC* -1.27 0.03* 
AAC 0.45 0.88 
GGC -3.98 0.08 
AGC 1.27 0.08 
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Figure 1: LD pattern of (r2) for the five  selected SNPs within the SNAP-25 
gene on chromosome 20 p12-p11.2.SNPs. (1), rs363039, (2) rs363043, (3) 
rs363050, (4) rs3746544, (5) rs1051312. 
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Figure 2: Main BOLD effect due to the paced overt categorical verbal 
fluency task: comparison among the three groups: healthy controls (HC)(10 
subjects), group 0 (10 AD patients carrying the rs363050(GG) and 
rs363043 (CC) genotypes), and group 1 (18 AD patients carrying the 
rs363050 (AA or AG) and rs363043 (CT or TT) genotypes)(ANOVA). Brain 
areas which are significantly more activated in: HC1 vs. AD group 0 (panel 
A); HC1 vs. AD group 1 (panel B); and AD group 0 vs. group 1 (panel C) 
are shown. See text for statistical thresholds and further details. The right 
side on the images corresponds to the left side of the brain. 
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Figure 3: Binomial logistic regression analysis of APOE association to 
ΔMMSE (panel A), ΔNPI (panel B) and ΔFLSA (Panel C). APOE4+ vs. 
APOE4- was considered as dependent variable, baseline values MMSEb, 
NPIb and FLSAb, age at baseline, level of education and gender were 
computed as covariates. 
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Figure 4: Box plot data were reported in figure 4 showing statistical 
association obtained after multinomial regression logistic analysis between 
delta scores variation in relationship with SNAP-25 rs363050 genotypes 
and ΔMMSE score, (panel A) ΔNPI scores (panel B), ΔFLSA scores (panel 
C). 
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Figure 5: Box plot data were reported in figure 5 showing statistical 
association obtained after multinomial regression logistic analysis between 
delta scores variation in relationship with SNAP-25 rs363039 genotypes 
and ΔMMSE score (panel D), ΔNPI scores (panel E), ΔFLSA scores (panel 
F). 
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